Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction

David Carrick,* Caroline Haig,* Annette M. Maznyczka, Jaclyn Carberry, Kenneth Mangion, Nadeem Ahmed, Vannesa Teng Yue May, Margaret McEntegart, Mark C. Pettie, Hany Eteiba, Mitchell Lindsay, Stuart Hood, Stuart Watkins, Andrew Davie, Ahmed Mahrous, Ify Mordi, Ian Ford, Aleksandra Radjenovic, Paul Welsh, Naveed Sattar, Kirsty Wetherall, Keith G. Oldroyd, Colin Berry

Abstract—The rationale for our study was to investigate the pathophysiology of microvascular injury in patients with acute ST-segment–elevation myocardial infarction in relation to a history of hypertension. We undertook a cohort study using invasive and noninvasive measures of microvascular injury, cardiac magnetic resonance imaging at 2 days and 6 months, and assessed health outcomes in the longer term. Three hundred twenty-four patients with acute myocardial infarction (mean age, 59 [12] years; blood pressure, 135 [25] / 79 [14] mm Hg; 237 [73%] male, 105 [32%] with antecedent hypertension) were prospectively enrolled during emergency percutaneous coronary intervention. Compared with patients without antecedent hypertension, patients with hypertension were older (63 [12] years versus 57 [11] years; P<0.001) and a lower proportion were cigarette smokers (52 [50%] versus 144 [66%]; P=0.007). Coronary blood flow, microvascular resistance within the culprit artery, infarct pathologies, inflammation (C-reactive protein and interleukin-6) were not associated with hypertension. Compared with patients without antecedent hypertension, patients with hypertension had less improvement in left ventricular ejection fraction at 6 months from baseline (5.3 [8.2]% versus 7.4 [7.6]%: P=0.040). Antecedent hypertension was a multivariable associate of incident myocardial hemorrhage 2-day post-MI (1.81 [0.98–3.34]; P=0.059) and all-cause death or heart failure (n=47 events, n=24 with hypertension; 2.53 [1.28–4.98]; P=0.007) postdischarge (median follow-up 4 years). Severe progressive microvascular injury is implicated in the pathophysiology and prognosis of patients with a history of hypertension and acute myocardial infarction.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02072850.
(Hypertension. 2018;72:720-730. DOI: 10.1161/HYPERTENSIONAHA.117.10786.) ● Online Data Supplement

Key Words: atherosclerosis ▼ hypertension ▼ myocardial infarction ▼ prognosis ▼ reperfusion injury

Hypertension has a continuous, age-related risk of mortality from ischemic heart disease. At least 30% of adults have a history of hypertension in developed countries, and hypertension is independently associated with adverse cardiac outcome after acute myocardial infarction (MI). However, the mechanisms for this association are unclear. Patients who present with acute ST-segment–elevation myocardial infarction (STEMI) and a history of hypertension are older and generally have a higher burden of risk factors, except for cigarette smoking which associates with male sex and younger age. The size of infarction is a key determinant of survival post-MI, but previous studies have not found any association between hypertension status and infarct size. Therefore, the mechanisms underlying the association between hypertension status and health outcomes post-MI remain unclear.

Hypertension is a risk factor for coronary heart disease. The pathophysiology includes left ventricular hypertrophy, coronary endothelial dysfunction, accelerated coronary atherosclerosis, abnormal coronary artery remodeling, coronary microvascular dysfunction, and epicardial fat. Accordingly, preexisting coronary heart disease may predispose patients with antecedent hypertension to enhanced myocardial reperfusion injury. Severe microvascular injury within the infarct zone manifests acutely as microvascular obstruction affecting about...
half of all-comers with STEMI,21,22 and subsequently resolving in half of these patients by 10 days.22 In patients with persistent microvascular obstruction, progressive irreversible capillary degradation occurs leading to infarct zone hemorrhage, which is an independent predictor of death or heart failure in the longer term.21,22 To date, the associations between antecedent hypertension and microvascular injury post-MI are unclear.

We investigated the natural history of hypertension status, microvascular pathology, and prognosis in all-comers with acute STEMI. We measured microvascular function directly in the culprit coronary artery acutely using a sensor mounted on an intra-coronary guidewire and noninvasively using the surface ECG. We subsequently used multiparametric cardiac magnetic resonance (CMR) to assess the evolution of infarct pathologies and left ventricular function and volumes at 2-day and 6-month post-MI.

We hypothesized that a history of hypertension would be associated with enhanced microvascular dysfunction within the culprit coronary artery acutely, and more abundant microvascular pathologies, including microvascular obstruction and myocardial hemorrhage, independent of the size of infarction, when assessed using CMR 2 days later. This hypothesis implicates microvascular damage within the infarct zone as an underpinning mechanism leading to less myocardial salvage, greater adverse left ventricular remodeling, and an increased risk of heart failure and death after an acute MI.

Methods
The data that support the findings of this study can be requested from the following URL: http://www.CORportal.net.

Study Population
We performed a prospective cohort study in a regional cardiac center between July 14, 2011, and November 22, 2012. Written informed consent was obtained from all of the participants.

A history of hypertension was prospectively recorded if patients were prescribed antihypertensive treatment or had successive blood pressure (BP) measurements that were ≥140/90 mm Hg on at least 2 different days during the index hospitalization.23 Noninvasive BP was measured in recumbent patients using an oscillometric method using an arm cuff pressure-sensitive transducer (GE CRITIKON, GE Healthcare, Amersham, United Kingdom) and automated medical patient monitoring system (DINAMAP and CARESCAPE Monitor B850, GE Medical Systems Information Technologies). Patients were categorized as having hypertension or not.

Patients were eligible if they had an indication for primary percutaneous coronary intervention (PCI) or thrombolysis for acute STEMI.24 Exclusion criteria included contraindications to CMR, for example, a pacemaker. The study was approved by the National Research Ethics Service (reference 10-S0703-28). Acute STEMI management followed contemporary guidelines24 (Methods in the online-only Data Supplement). The ClinicalTrials.gov identifier is URL: http://www.clinicaltrials.gov. Unique identifier: NCT02072850.

Electrocardiogram
A 12-lead ECG was obtained before coronary reperfusion and 60 minutes afterward. The extent of ST-segment resolution on the ECG was measured in a research laboratory using an electrochemiluminescence method (e411, Roche) and the manufacturers’ calibrators and quality control material. The limit of detection for IL-6 and NT-proBNP was 0.1 pg/mL and the intra-assay coefficient of variation was 9.1%. NT-proBNP (N-terminal Pro-B-type natriuretic peptide) was measured in a research laboratory using an electrochemiluminescence method (e411, Roche) and the manufacturers’ calibrators and quality control material. The limit of detection for IL-6 and NT-proBNP are 6.5 pg/mL and 5 pg/mL respectively. Long-term coefficients of variations of low and high controls are typically <5% and were all within the manufacturers’ range.

CMR Imaging
We used CMR to provide reference data on left ventricular function, pathology, and surrogate outcomes (Figure 1). CMR was performed on a Siemens MAGNETOM Avanto (Erlangen, Germany) 1.5-Tesla scanner with a 12-element phased array cardiac surface coil.25 The imaging protocol24–27 (Methods in the online-only Data Supplement) included cine CMR with steady-state free precession, T2-mapping,22,23,27 T2*-mapping,22 and delayed-enhancement phase-sensitive inversion-recovery pulse sequences.28 The scan acquisitions were spatially coregistered and also included different slice orientations to enhance diagnostic confidence.

Imaging Analyses
The CMR analyses are described in detail in the online-only Data Supplement. Left ventricular dimensions were indexed to body surface area.
before coronary angioplasty was 109/71 mm Hg and measured 99/60 mm Hg postcoronary angioplasty. Microvascular resistance in the culprit coronary artery hypertension. The symptom-to-balloon time was 2.2 h. The angiogram also revealed a proximal occlusion of the left anterior descending artery. Blood pressure before coronary angioplasty was 200/125 mm Hg and measured 181/117 mm Hg postcoronary angioplasty. Two days later, CMR disclosed myocardial hemorrhage specifically revealed by T2* mapping (yellow arrows) and transmural infarction of the anterosetal wall of the left ventricle (LV; yellow arrows) associated with microvascular obstruction revealed by contrast CMR. Invasive assessment of microvascular function using a diagnostic guidewire placed in the culprit coronary artery at the end of primary PCI indicated severe microvascular injury. The index of microvascular resistance measured 92 which is substantially increased (reference range <25). The initial infarct size was 38.9%, and the LV ejection fraction (LVEF) and LV end-diastolic volume indexed to body surface area (LVEDVi) were 48.5% and 90.2 mL/m², respectively. Six months later, infarct size was 26.7% of LV mass, and the LV EVDVi was 127 mL/m². This is in-keeping with >20% in LV EVDVi, that is, adverse remodeling. This patient went to have an unplanned admission for heart failure treatment on day 493 of follow-up.

Infarct Definition and Size
The presence of acute infarction was established based on abnormalities in cine wall motion, rest first-pass myocardial perfusion, and delayed-enhancement imaging in 2 imaging planes. The myocardial mass of late gadolinium (grams) was quantified using computer-assisted planimetry and the territory of infarction was delineated using a signal intensity threshold of >5 SDs above a remote reference region and expressed as a percentage of total left ventricular mass.39

Microvascular Obstruction
Microvascular obstruction was defined as a dark zone on early gadolinium enhancement imaging 1, 3, 5, and 7-minute postcontrast injection that remained present within an area of late gadolinium enhancement at 15 minutes.

Myocardial Edema
The extent of myocardial edema was defined as left ventricular myocardium with pixel values (T2) >2 SDs from remote myocardium.40–42

Myocardial Salvage
Myocardial salvage was calculated by subtraction of percent infarct size from percent area-at-risk, as reflected by the extent of edema.40–42 The myocardial salvage index was calculated by dividing the myocardial salvage area by the initial area-at-risk.

Left Ventricular Remodeling
An increase in left ventricular volume at 6 months from baseline was taken to reflect left ventricular remodeling.35

Myocardial Hemorrhage
On the T2* CMR maps, a region of reduced signal intensity within the infarcted area, with a T2* value of <20 ms43,44 was considered to confirm the presence of myocardial hemorrhage.

Prespecified Health Outcomes
We prespecified adverse health outcomes that are pathophysiologically linked with STEMI.44,45 The primary composite outcome was (1) all-cause death or first heart failure event after the initial hospitalization (Methods in the online-only Data Supplement).

Statistical Analyses
The sample size calculation and statistical methods are described in the online-only Data Supplement. All P values are 2-sided and a P value >0.05 indicates the absence of a statistically significant effect. Statistical analyses were performed using R version 2.15.1 or SAS v 9.3 or higher versions of these programs.

Results

Patient Characteristics
Of 372 patients with acute STEMI who were screened, 324 (mean age, 59 [12] years; 237 [73%] male, 105 [32%] with hypertension) were enrolled (Table 1; Figure 2). The reasons for not being enrolled in the study are detailed in Figure 2. None of the participants had a new diagnosis of hypertension during the index admission.
Table 1. Clinical and Angiographic Characteristics of 324 STEMI Patients Categorized According to a History of Hypertension

| Characteristics* | All Patients | No History of Hypertension | History of Hypertension | P Value |
|------------------|--------------|----------------------------|-------------------------|---------|
|                  | n=324 | n=154 | n=63 | n=67 | n=38 |<0.001 (A) | 0.226 | 0.069 (A) |
| Age, y           | 59 (12) | 58 (11) | 55 (10) | 66 (11) | 60 (12) |<0.001 (A) | 0.023 | <0.001 (A) |
| Male sex, n (%)  | 237 (73) | 110 (71) | 52 (83) | 45 (67) | 28 (74) |0.226 | 0.113 | 0.583 |
| BMI, kg/m²       | 29 (5) | 28 (5) | 29 (5) | 29 (5) | 30 (4) |0.069 (A) | 0.012 (A) | 0.012 (A) |
| Medical history  |                       |                       |                       |         |         |         |         |         |
| Current smoking, n (%) | 196 (61) | 101 (66) | 42 (67) | 30 (45) | 22 (58) |0.023 | 0.226 | 0.113 |
| Hypercholesterolemia, n (%) | 94 (29) | 33 (21) | 9 (14) | 33 (49) | 18 (47) |<0.001 (A) | 0.113 |<0.001 (A) |
| Diabetes mellitus†, n (%) | 34 (11) | 15 (10) | 3 (5) | 12 (18) | 4 (11) |0.113 | 0.113 | 0.113 |
| Previous angina, n (%) | 40 (12) | 17 (11) | 5 (8) | 10 (15) | 8 (21) |0.224 | 0.224 | 0.224 |
| Previous myocardial infarction, n (%) | 25 (8) | 8 (5) | 5 (8) | 7 (10) | 4 (11) |0.374 | 0.374 | 0.374 |
| Previous PCI, n (%) | 18 (6) | 7 (5) | 5 (8) | 5 (8) | 1 (3) |0.583 | 0.583 | 0.583 |
| Presenting characteristics |                       |                       |                       |         |         |         |         |         |
| Heart rate, bpm   | 78 (17) | 75 (16) | 82 (19) | 77 (15) | 82 (17) |0.012 (A) | 0.001 (A) | 0.001 (A) |
| Systolic blood pressure, mm Hg | 135 (25) | 124 (17) | 159 (16) | 124 (20) | 163 (18) |<0.001 (A) |<0.001 (A) |<0.001 (A) |
| Diastolic blood pressure, mm Hg | 79 (14) | 73 (10) | 93 (9) | 71 (11) | 95 (9) |<0.001 (A) |<0.001 (A) |<0.001 (A) |
| Symptom onset to reperfusion time, min | 174 (120–315) | 171 (112–313) | 208 (132–318) | 209 (129–445) | 144 (110–220) |0.028 (KW) | 0.028 (KW) | 0.028 (KW) |
| Ventricular fibrillation‡, n (%) | 21 (7) | 10 (7) | 1 (2) | 9 (13) | 1 (3) |0.045 | 0.045 | 0.045 |
| Killip class at presentation, n (%) |                       |                       |                       |         |         |         |         |         |
| I                | 233 (72) | 116 (75) | 42 (67) | 43 (64) | 31 (82) |0.127 | 0.127 | 0.127 |
| II               | 68 (21) | 31 (20) | 16 (25) | 14 (21) | 6 (16) |0.127 | 0.127 | 0.127 |
| III/IV           | 23 (7) | 7 (5) | 5 (8) | 10 (15) | 1 (3) |0.127 | 0.127 | 0.127 |
| ST-segment resolution, n (%) |                       |                       |                       |         |         |         |         |         |
| Complete ≥70%    | 148 (46) | 81 (53) | 25 (40) | 30 (46) | 11 (29) |0.166 | 0.166 | 0.166 |
| Incomplete 30% to <70%    | 127 (39) | 54 (35) | 28 (44) | 26 (39) | 18 (47) |0.166 | 0.166 | 0.166 |
| None ≤30%        | 48 (15) | 19 (12) | 10 (16) | 10 (15) | 9 (24) |0.166 | 0.166 | 0.166 |
| Reperfusion strategy, n (%) |                       |                       |                       |         |         |         |         |         |
| Primary PCI      | 302 (93) | 144 (94) | 60 (95) | 61 (91) | 35 (92) |0.804 | 0.804 | 0.804 |
| Rescue PCI (failed thrombolysis) | 14 (4) | 5 (3) | 2 (3) | 5 (8) | 2 (5) |0.804 | 0.804 | 0.804 |
| Successful thrombolysis | 8 (3) | 5 (3) | 1 (2) | 1 (2) | 1 (3) |0.804 | 0.804 | 0.804 |
| Coronary angiography |                       |                       |                       |         |         |         |         |         |
| No. of diseased arteries§, n (%) |                       |                       |                       |         |         |         |         |         |
| 1                | 174 (54) | 94 (61) | 28 (44) | 37 (55) | 13 (34) |0.037 | 0.037 | 0.037 |
| 2                | 99 (31) | 43 (28) | 23 (37) | 17 (25) | 16 (42) |0.037 | 0.037 | 0.037 |
| 3                | 45 (14) | 14 (9) | 12 (19) | 11 (16) | 8 (21) |0.037 | 0.037 | 0.037 |
| Culprit coronary artery, n (%) |                       |                       |                       |         |         |         |         |         |
| LM               | 6 (2) | 3 (2) | 0 | 2 (3) | 1 (3) |0.208 | 0.208 | 0.208 |
| LAD              | 121 (37) | 61 (40) | 27 (43) | 24 (36) | 9 (24) |0.208 | 0.208 | 0.208 |
| LCX              | 59 (18) | 25 (16) | 14 (22) | 8 (12) | 10 (26) |0.208 | 0.208 | 0.208 |
| RCA              | 144 (44) | 68 (44) | 22 (35) | 35 (52) | 19 (50) |0.208 | 0.208 | 0.208 |
| TIMI coronary flow grade pre-PCI, n (%) |                       |                       |                       |         |         |         |         |         |
| 0/1              | 236 (73) | 108 (70) | 49 (78) | 47 (70) | 31 (82) |0.398 | 0.398 | 0.398 |
| 2/3              | 88 (27) | 46 (30) | 14 (22) | 20 (30) | 7 (18) |0.398 | 0.398 | 0.398 |

(Continued)
### Table 1. Continued

| Characteristics* | All Patients | No History of Hypertension | History of Hypertension | P Value |
|------------------|-------------|----------------------------|-------------------------|---------|
|                  | n=324       | n=154                      | n=63                    |         |
|                  | n=67        | n=38                       |                         |         |
| TIMI coronary flow grade post-PCI, n (%) |             |                            |                         | 0.052   |
| 0/1              | 4 (1)       | 0                          | 2 (3)                   |         |
| 2/3              | 320 (99)    | 154 (100)                  | 61 (97)                 |         |
|                  |             |                            | 65 (97)                 |         |
| Microvascular function (angiography) |             |                            |                         |         |
| TIMI frame count pre-PCI | 30 (18–47) | 28 (18–43)                 | 24 (16–28)              | 38 (28–58) | 34 (19–42) | 0.068 (KW) |
| TIMI frame count post-PCI | 16 (10–25) | 14 (10–23)                 | 17 (12–30)              | 18 (10–24) | 19 (10–26) | 0.266 (KW) |
| TIMI blush grade post-PCI, n (%) |             |                            |                         | 0.505   |
| 0                | 70 (23)     | 33 (23)                    | 15 (25)                 | 13 (20)  | 9 (24)     |         |
| 1                | 17 (6)      | 5 (3)                      | 4 (7)                   | 7 (11)   | 1 (3)      |         |
| 2                | 157 (51)    | 71 (49)                    | 28 (48)                 | 35 (54)  | 21 (57)    |         |
| 3                | 65 (21)     | 37 (25)                    | 12 (20)                 | 10 (15)  | 6 (16)     |         |
| Microvascular function (intracoronary sensor) |             |                            |                         |         |
| Index of microvascular resistance | 24 (15–44) | 26 (15–43)                 | 23 (15–37)              | 24 (15–50) | 25 (17–49) | 0.929 (KW) |
| Coronary flow reserve | 1.6 (1.1–2.1) | 1.5 (1.1–2.0) | 1.8 (1.2–2.3) | 1.6 (1.1–2.1) | 1.4 (1.1–1.8) | 0.170 (KW) |
| Resistance reserve ratio | 1.8 (1.4–2.5) | 1.8 (1.3–2.5) | 2.3 (1.7–3.0) | 1.8 (1.3–2.3) | 1.8 (1.5–2.3) | 0.261 (KW) |
| Treatment in the catheter laboratory, n (%) |             |                            |                         |         |
| Aspiration thrombectomy | 236 (73) | 107 (70)                    | 52 (83)                 | 49 (73)  | 27 (71)    | 0.254   |
| Glycoprotein IIb/IIIa inhibitor | 297 (92) | 144 (94)                    | 56 (89)                 | 59 (88)  | 36 (95)    | 0.402   |
| Medical therapy |             |                            |                         |         |
| ACE-I or ARB | 320 (99)    | 151 (98)                   | 62 (98)                 | 67 (100) | 38 (100)   | 0.796   |
| β-Blocker       | 308 (95)    | 142 (92)                   | 61 (97)                 | 67 (100) | 36 (95)    | 0.058   |
| Statin          | 324 (100)   | 154 (100)                  | 63 (100)                | 67 (100) | 38 (100)   | 1.000   |
| Antithrombotic therapy at discharge |             |                            |                         |         |
| Aspirin         | 323 (100)   | 153 (99)                   | 63 (100)                | 67 (100) | 38 (100)   | 1.000   |
| Clopidogrel     | 321 (99)    | 152 (99)                   | 62 (98)                 | 67 (100) | 38 (100)   | 0.796   |
| Blood results on admission |             |                            |                         |         |
| Creatinine, µg/L | 76 (65–89) | 74 (65–87)                 | 75 (64–87)              | 77 (70–91) | 79 (65–98) | 0.276 (KW) |
| C-reactive protein, mg/L | 4 (2–7) | 3 (2–6)                    | 4 (2–8)                 | 3 (2–9)  | 4 (2–7)    | 0.233 (KW) |
| Interleukin-6, pg/mL | 7 (4–11) | 7 (4–10)                    | 6 (5–11)                | 8 (4–21) | 9 (6–15)   | 0.503 (KW) |
| NT-proBNP | 864 (345–1637) | 651 (322–1437) | 1208 (352–1637) | 1208 (576–1924) | 702 (299–1175) | 0.310 (KW) |
| Troponin T, ng/L | 1710 (110–5099) | 1628 (256–4375) | 1504 (106–5580) | 1931 (101–5244) | 1981 (210–5108) | 0.976 (KW) |

Killip classification of heart failure after acute myocardial infarction: class I, no heart failure; class II, pulmonary rales or crepitations, a third heart sound, and elevated jugular venous pressure; class III, acute pulmonary edema; class IV, cardiogenic shock. ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LM, left main coronary artery; NT-proBNP, N-terminal Pro-B-type natriuretic peptide; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment–elevation myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction.

*Data are reported as mean (SD), median (interquartile range), or N (%) as appropriate. P values have been obtained from 1-way ANOVA (A), Kruskal-Wallis test (KW), or Fisher test. TIMI flow grades pre- and post-PCI were grouped 0/1 vs 2/3 for this analysis.

†Diabetes mellitus was defined as a history of diet-controlled or treated diabetes mellitus.

‡Successfully electrically cardioverted ventricular fibrillation at presentation or during emergency PCI procedure.

§Multivessel coronary artery disease was defined according to the number of stenoses of at least 50% of the reference vessel diameter, by visual assessment and whether or not there was left main stem involvement. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) in the table represent measurements obtained at the start of emergency PCI. High blood pressure is defined as having SBP >140 mm Hg and DBP >80 mm Hg during the index admission.
Compared with patients without a history of hypertension, patients with a history of hypertension were older, had a history of hypercholesterolemia more often, but a history of cigarette smoking less often, and were more likely to have ventricular fibrillation at presentation and multivessel coronary artery disease (Table 1).

**Microvascular Injury in the Culprit Coronary Artery and Inflammation**

Angiographic parameters of blood flow and perfusion in the culprit coronary artery, IMR, and ST-segment resolution on the ECG (none versus partial versus complete) were similar between the groups (Table 1).

On day 1, circulating CRP, IL-6, and neutrophils and monocyte levels were also similar between the groups (Table 1).

**CMR Imaging Findings**

Three hundred twenty-four patients underwent CMR imaging 2.0 (1.8) days later, and 300 (93%) patients had follow-up CMR at 6 months (Table 2; Figure 2). Case examples are shown in Figure 1.

Infarct size was similar in patients with or without a history of hypertension (Table 2). However, left ventricular mass index at baseline was associated with a history of hypertension in men (Table 2) and in both men and women with hypertension at 6-month post-STEMI (Table 2).

Left ventricular ejection fraction improved in all patients, however, compared with patients without a history of hypertension, the increase in ejection fraction was less in patients with a history of hypertension (Table 2).

**Sex Differences and History of Hypertension**

Left ventricular mass reduced to a lesser extent by 6 months in women with hypertension compared with in women without hypertension (Table 2).

**BP at Initial Presentation**

We observed associations between BP at the start of emergency PCI (normal BP [systolic BP ≤140 mmHg; diastolic BP ≤80 mmHg]; high BP [systolic BP >140 mmHg; diastolic BP >80 mmHg] and clinical characteristics notably body mass index [normal BP versus high BP: 28.4 (4.8) versus 29.6 (4.7) kg/m²; \( P=0.042 \)] but not vascular risk factors [smoking \( P=0.54 \); hypercholesterolemia \( P=0.59 \)] and microvascular dysfunction at the end of PCI as revealed by ST-segment elevation myocardial infarction.
Table 2. Cardiac MRI Findings at 2 Days and 6 Months Postreperfusion in 324 STEMI Patients Categorized According to History of Hypertension

| Characteristics | All Patients | No History of Hypertension | History of Hypertension | P Value |
|-----------------|-------------|---------------------------|------------------------|---------|
|                 | n=321       | n=153                     | n=63                   | n=65    | n=38    |
| CMR findings 2-d post-MI |             |                           |                        |         |
| LV ejection fraction, % | 55 (10)   | 55 (10)                   | 53 (9)                 | 56 (10)  | 56 (9)  | 0.178 (A)  |
| LV end-diastolic volume index, mL/m² |             |                           |                        |         |
| Men              | 82 (15)     | 82 (14)                   | 83 (15)                | 82 (17)  | 83 (15) | 0.958 (A)  |
| Women            | 72 (12)     | 73 (12)                   | 73 (16)                | 73 (10)  | 70 (13) | 0.901 (A)  |
| LV end-systolic volume index, mL/m² |             |                           |                        |         |
| Men              | 38 (13)     | 39 (14)                   | 40 (13)                | 37 (14)  | 38 (11) | 0.804 (A)  |
| Women            | 32 (10)     | 32 (10)                   | 35 (10)                | 32 (9)   | 29 (9)  | 0.516 (A)  |
| LV mass index, g/m² |             |                           |                        |         |
| Men              | 73 (15)     | 70 (14)                   | 76 (13)                | 76 (17)  | 77 (16) | 0.019 (A)  |
| Women            | 58 (10)     | 55 (8)                    | 64 (15)                | 58 (9)   | 61 (14) | 0.065 (A)  |
| Infarct characteristics |             |                           |                        |         |
| Infarct size, %LV mass | 16 (7 to 27) | 15 (5 to 25)              | 19 (8 to 33)           | 20 (7 to 29) | 15 (7 to 22) | 0.102 (KW) |
| Myocardial salvage index, % of LV mass | 63 (24) | 66 (26)                 | 58 (25)                | 61 (22)  | 63 (19) | 0.174 (KW) |
| Late microvascular obstruction, n (%) | 164 (51) | 75 (49)                  | 33 (52)                | 36 (54)  | 19 (50) | 0.902 (A)  |
| Late microvascular obstruction, %LV mass | 0 (0 to 4) | 0 (0 to 3)               | 1 (0 to 4)            | 1 (0 to 6) | 0 (0 to 3) | 0.342 (KW) |
| Myocardial hemorrhage, n (%) | 101 (41) | 44 (38)                  | 20 (39)                | 25 (49)  | 12 (46) | 0.514 (A)  |
| CMR findings 6-mo post-MI (n=267) |             |                           |                        |         |
| LV ejection fraction at 6 mo, % | 63 (57 to 69) | 64 (59 to 70)           | 60 (55 to 66)          | 62 (54 to 69) | 65 (59 to 71) | 0.049 (KW) |
| Change in LV ejection fraction at 6 mo, % | 7 (8) | 8 (8)                    | 7 (7)                  | 4 (7)    | 7 (10)  | 0.037 (A)  |
| LV mass index, g/m² |             |                           |                        |         |
| Men              | 63 (56 to 71) | 61 (54 to 69)            | 63 (57 to 71)          | 67 (59 to 77) | 68 (62 to 74) | 0.004 (KW) |
| Women            | 53 (9)      | 49 (6)                   | 54 (6)                 | 57 (10)  | 60 (9)  | <0.001 (A) |
| Change in LV mass index at 6 mo, g/m² |             |                           |                        |         |
| Men              | −8 (13)     | −7 (14)                   | −10 (13)               | −7 (12)  | −7 (9)  | 0.641 (A)  |
| Women            | −5 (8)      | −7 (7)                    | −6 (8)                 | 0 (11)   | −4 (5)  | 0.022 (A)  |
| LV end-systolic volume index at 6 mo, mL/m² |             |                           |                        |         |
| Men              | 32 (23 to 41) | 30 (22 to 37)            | 35 (28 to 41)          | 33 (22 to 43) | 31 (22 to 36) | 0.208 (KW) |
| Women            | 27 (10)     | 25 (10)                   | 29 (10)                | 30 (10)  | 26 (10) | 0.231 (A)  |
| Change in LV end-systolic volume index at 6 mo, mL/m² |             |                           |                        |         |
| Men              | −4 (13)     | −5 (13)                   | −4 (10)                | 0 (15)   | −6 (13) | 0.179 (A)  |
| Women            | −5 (8)      | −6 (7)                    | −7 (8)                 | −2 (9)   | −4 (9)  | 0.182 (A)  |

BMI indicates body mass index; BP, blood pressure; CMR, cardiac magnetic resonance; LV, left ventricle; MI, myocardial infarction; MRI, magnetic resonance imaging; and STEMI, ST-segment–elevation myocardial infarction.

Area-at-risk was measured with T2-mapping. Data are given as n (%) or mean (SD). P values were obtained from a 1-way ANOVA (A), Kruskal-Wallis test (KW), or a Fisher test. Native T1 (ms) was not associated with hypertension status (antecedent hypertension, yes vs no: remote zone, P=0.266; infarct zone, P=0.508; infarct core, P=0.205). High blood pressure is defined as having systolic BP (SBP)> 140 mm Hg and diastolic BP (DBP)>80 mm Hg during the index admission.

* Data are reported as mean (SD), median (interquartile range), or n (%) as appropriate. LV ejection fraction was missing in 24 subjects at follow-up. LV end-diastolic volume index at follow-up was missing in 16 men and 8 women.
resolution (complete, none, partial: [normal BP versus high BP] 111 [50.5%], 29 [13.2%], 80 [36.4%] versus 36 [35.6%], 19 [18.8%], 46 [45.5%]; \( P=0.041 \)).

**Multivariable Associations Between Hypertension and Coronary Microvascular Pathology**

**Myocardial Hemorrhage**

In a binary logistic regression model with baseline characteristics, a history of hypertension was a multivariable associate of myocardial hemorrhage (odds ratio, 1.81; [95% confidence interval, 0.98–5.34]; \( P=0.059 \); Table 3), albeit with wide confidence intervals.

**Microvascular Dysfunction and Health Outcomes in the Longer Term**

All \((n=324)\) of the patients had long-term follow-up data completed. The median duration of follow-up was 1500 days (postdischarge censor duration [range] 1236 to 1801 days). Forty-seven (15%) patients died or experienced a first heart failure event during the index hospitalization or postdischarge. These events included 4 cardiovascular deaths, 11 noncardiovascular deaths, 2 deaths of undetermined cause, and 30 episodes of heart failure (Killip class 3 or 4 heart failure \((n=28)\) or defibrillator implantation \((n=2)\)). Twenty-three (7%) patients died or experienced a first heart failure hospitalization postdischarge.

A history of hypertension (odds ratio, 2.53; [95% confidence interval, 1.28–4.98]; \( P=0.007 \)) was a multivariable associate of all-cause death or heart failure (Table 4).

**Discussion**

We have undertaken a large prospective imaging cohort study of hypertension status, microvascular pathophysiology, and long-term prognosis in patients with an acute STEMI. Uniquely, our study enrolled a high proportion of screened patients (nearly 9 of every 10 assessed), followed by serial multimodality assessments including use of invasive and noninvasive tests of reperfusion injury, circulating measures of inflammation, serial imaging of infarct pathology and remodeling, and follow-up for health outcomes over a median of 4 years in all of the study participants.

The main findings are that antecedent hypertension was associated with (1) older age and less cigarette smoking; (2) a 2-fold increased likelihood of myocardial hemorrhage, albeit with wide confidence intervals, and less improvement in left ventricular systolic function at 6 months; (3) sex differences, specifically, for the associations between hypertension status and left ventricular outcomes in women but not in men; and (4) >2-fold increased risk of all-cause death or heart failure during a median of 4 years follow-up. Antecedent hypertension was not associated with infarct size, reperfusion injury, or systemic inflammation. BP status at initial presentation was associated with age, body mass index, and reperfusion injury as revealed by ST-segment resolution at the end of the PCI procedure.

**Hypertension and Prognosis After Acute STEMI**

In line with prior studies,\(^{11,12}\) we found that a history of hypertension is associated with risk factors for cardiovascular disease including age, smoking (less common),\(^{46}\) and hypercholesterolemia (more common).

We also found that a history of hypertension was independently associated with an increased risk of all-cause death or hospitalization for heart failure. This result extends the evidence from previous studies. Notably, Reinstadler et al\(^ {11} \) found that antecedent hypertension was associated with a >3-fold risk of major adverse cardiac events at 12 months in a clinical trial population of 792 patients with acute STEMI.

**Antecedent Hypertension, Sex, and Remodeling**

Recent studies have reported conflicting information on the associations between antecedent hypertension and sex.\(^ {11,12} \) Changes in left ventricular ejection fraction and remodeling at 6 months, including left ventricular end-systolic volume and mass, were less favorable in women with hypertension compared with women without hypertension. The enhanced

---

**Table 3. Multivariable Binary Logistic Regression Model of the Associations Between Clinical Characteristics, Including a History of Hypertension (Present or Absent), and the Occurrence of Myocardial Hemorrhage (Yes or No) 2 Days Later (n=324) in Patients With Acute STEMI**

| Binary Logistic Regression | Odds Ratio (95% Confidence Interval) | \( P \) Value |
|---------------------------|--------------------------------------|--------------|
| TIMI coronary flow grade 2/3 pre-PCI, n (%) | 0.25 (0.12–0.51) | <0.001 |
| ST-segment elevation resolution post-PCI, n (%) | |
| Incomplete 30% to <70% | 2.44 (1.31–4.53) | 0.005 |
| None ≤30% | 3.90 (1.69–9.02) | 0.001 |
| Cigarette smoker | 2.55 (1.39–4.70) | 0.003 |
| Male sex | 2.67 (1.33–5.38) | 0.006 |
| Hypertension | 1.81 (0.98–3.34) | 0.059 |
| Harrel’s C statistic: 0.746 |

Manual backwards selection was used with a \( P \) value threshold of 0.10 for inclusion. Previous PCI was excluded because of numeric instability. The C statistic reflects the whole model. The univariable association between hypertension and myocardial hemorrhage was 1.5 (0.87–2.59); \( P=0.143 \). PCI indicates percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction.

---

**Table 4. Multivariable Binary Logistic Regression Model for the Composite End Point (Yes or No) of All-Cause Death or First Hospitalization for Heart Failure, Including Clinical Characteristics (Present or Absent) at Baseline**

| Binary Logistic Regression | Odds Ratio (95% Confidence Interval) | \( P \) Value |
|---------------------------|--------------------------------------|--------------|
| History of myocardial infarction | 6.19 (2.40–15.95) | <0.001 |
| ST-segment elevation resolution post-PCI, n (%) | |
| Incomplete 30% to <70% | 3.41 (1.54–7.56) | 0.005 |
| None ≤30% | 4.13 (1.55–11.06) | 0.001 |
| Cigarette smoker | 2.55 (1.39–4.70) | 0.003 |
| Hypertension | 2.53 (1.28–4.98) | 0.007 |
| Harrel’s C statistic: 0.746 |

The median duration of follow-up was 4 y (1500 d [postdischarge censor duration (range) 1236–1801 d]). Forty-seven (15%) patients died or experienced a first heart failure event during the index hospitalization or postdischarge. Manual backwards selection was used with a \( P \) value threshold of 0.10 for inclusion. The C statistic reflects the whole model. The univariable association between hypertension and all-cause death or first hospitalization for heart failure was 2.52 (1.35–4.73); \( P=0.004 \). PCI indicates percutaneous coronary intervention.
left ventricular mass in women with hypertension post-MI predisposes these individuals to adverse remodeling post-MI, and potentially, a worse cardiac prognosis in the longer term. Since the mean age of the participants was 59 years, an accelerated cardiovascular risk in postmenopausal women may be one contributing factor. Although reductions in mortality attributable to coronary heart disease have been observed in recent decades, no such decline has been observed in younger (<55 years) women. Further research seems warranted.

**Antecedent Hypertension, Microvascular Function, and Myocardial Hemorrhage Post-MI**

We studied the relationships between microvascular resistance measured directly in the culprit coronary artery at the time of the acute STEMI and antecedent hypertension. Surprisingly, hypertension was not associated with acute reperfusion injury, as revealed by direct intracoronary measurements of microvascular resistance and by angiographic parameters (TIMI frame count, TIMI blush grade) or ST-segment resolution. The potential explanations for this finding include the prior use of anti-hypertensive therapies, such as angiotensin-converting enzyme inhibitors, which have protective effects on vascular function, and the similar levels of arterial BP at the time of hospital admission in patients with a history of hypertension compared with BP levels in patients with no history of hypertension. This finding is in-keeping with the beneficial effects of both lifestyle and pharmacological measures to control BP. Because all of these parameters of coronary microvascular function are associated with prognosis post-MI, our findings rule out enhanced microvascular injury within the infarct zone as an explanation for the adverse prognosis in patients with antecedent hypertension.

Myocardial hemorrhage occurs in about one-third of patients with acute STEMI. This pathology reflects the end-stage consequence of irreversible microvascular dysfunction and is independently associated with adverse cardiac outcomes. In a time-course study, we have previously shown that myocardial hemorrhage occurs in 2 phases after coronary reperfusion. The first phase occurs acutely within 12 hours. The second phase involves new, secondary bleeds that occur between days 1 and 3 in previously unaffected patients. In this study, all patients who had evidence of new myocardial hemorrhage on day 3 had prior evidence of microvascular obstruction at 12 hours. We think that the temporal relationships between microvascular obstruction and myocardial hemorrhage may be relevant when considering their associations with hypertension status.

Microvascular function measured acutely and microvascular obstruction revealed by CMR 2 days later were not associated with hypertension status. However, myocardial hemorrhage, as specifically revealed by T2* mapping (Figure 1) was associated with a near 2-fold increased risk of hypertension, independent of other predictors. The result was not statistically significant and thus hypothesis generating. Cigarette smoking status is a multivariable, positive associate of myocardial hemorrhage after an acute STEMI (Table 3) and the inverse association between hypertension and smoking status may be a relevant confounding factor.

We undertook a time-course study with repeated assessments to assess the temporal evolution of microvascular injury acutely and then subsequently 2 to 3 days later using CMR. Long-term follow-up of this cohort permitted an analysis of the prognostic significance of microvascular injury early post-MI. Myocardial hemorrhage reflects vascular degradation and capillary leak of red blood cells. Hemorrhage within the infarct zone as revealed by CMR (Figure 1) is a direct measure of end-stage vascular injury post-MI. Our findings lead to a conclusion that despite a similar extent of acute microvascular injury and infarct size, vascular degradation at 2 days is greater in patients with a history of hypertension compared with patients with no prior hypertension. We hypothesize that the microvessels of patients with hypertension are less capable of maintaining vascular integrity under conditions of ischemia/reperfusion injury. Given that hemorrhage may develop progressively in a secondary phase (days 2–3), impaired vascular homeostasis and repair potential in patients with chronic hypertension may be explanations for these results. Such patients may have preexisting coronary microvascular disease, and the microvessels subtyped by the culprit artery may be less resistant to the effects of reperfusion injury (acidosis, oxidants, etc), leading to progressive capillary degradation and infarct zone hemorrhage. A susceptibility to hemorrhagic transformation within the infarct zone may provide a new mechanistic explanation for why patients with antecedent hypertension have a worse prognosis despite infarct size being similar to patients without prior hypertension. Accumulation of deoxyhemoglobin and iron within the infarct zone may serve as a mechanistic substrate for enhanced scar formation and abnormal left ventricular remodeling. Our results suggest that progressive microvascular damage within the infarct zone in patients with antecedent hypertension may underpin an impaired recovery potential within the heart, leading in turn to left ventricular systolic dysfunction and heart failure in the longer term.

We did not find any association between hypertension status and infarct size, as reflected by contrast-enhanced CMR and peak troponin concentration. This result is consistent with reports by Reinstadler et al and De Luca et al. We did not observe any association between hypertension status and circulating measures of inflammation. This result could potentially be explained by the anti-inflammatory effects of antihypertensive drug therapies, such as angiotensin-converting enzyme inhibitors.

Our results provide further evidence that a history of hypertension in patients with an acute STEMI is associated with a worse prognosis. In terms of clinical translation, our results highlight that patients with a history of hypertension are at an increased risk of developing heart failure. The results support further research into therapeutic strategies designed to preserve vascular integrity and repair potential within the vascular distribution of the culprit coronary artery.

**Limitations**

Our analysis does not permit inference on causality, and further studies are warranted. We lacked detailed information on BP history and compliance with antihypertensive drug therapy before the index hospitalization.

**Perspectives**

In summary, we have studied the complex relationships between hypertension status, concomitant risk factors,
infarct pathology, left ventricular remodeling, and health outcomes in a large cohort of STEMI patients. We found that a history of hypertension in patients with acute STEMI is independently associated less improvement in left ventricular systolic function, notably in women, and an increased risk of all-cause death and heart failure in the longer term. An increased propensity to myocardial hemorrhage may be one mechanistic explanation, reflecting severe microvascular injury.

Our results confirm and extend previous investigations and support further research into therapeutic strategies that attenuate reperfusion injury within the infarct zone in patients with acute STEMI.

Acknowledgments
We thank the patients who participated in this study and the staff in the Cardiology and Radiology Departments. We thank Peter Weale and Patrick Revell (Siemens Healthcare, United Kingdom).

Sources of Funding
This study was supported by the British Heart Foundation (BHF) Centre of Research Excellence Award (RE/13/5/30177), the BHF Project Grant PG/11/2/28474, the National Health Service, and the Chief Scientist Office. C. Berry was supported by a Senior Fellowship from the Scottish Funding Council. P. Welsh is supported by BHF Fellowship FS/12/62/29889. A.M. Maznyczka is supported by BHF Fellowship FS/16/74/32573.

Disclosures
Based on institutional agreements with the University of Glasgow, Siemens Healthcare has provided work-in-progress imaging methods and C. Berry has acted as a consultant to Abbott Vascular. K.G. Oldroyd has acted as consultant to Abbott Vascular and Volcano Corporation. These companies had no involvement in the current research or the article. The other authors report no conflicts.

References
1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913. doi: 10.1016/S0140-6736(02)11191-8.
2. Benjamin EJ, Blaha MJ, Chiuve SE, et al; American Heart Association Council on Science and Public Health; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e136–e603. doi: 10.1161/CIRCULATIONAHA.100.028485.
3. British Heart Foundation. Cardiovascular Disease Statistics Factsheet (UK). https://www.bhf.org.uk/statistics. Accessed April 27, 2018.
4. Thune JJ, Spaulding C, Belliand B, Comito V, Vergara R, Migliorini A, Valenti R, Antonucci D. Impact of hypertension on infarct size in ST elevation myocardial infarction patients undergoing primary angioplasty. J Hypertens. 2013;31:2433–2437. doi: 10.1097/HJH.0b013e32836436fe.
5. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease—six-year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–45.
6. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med. 1970;72:813–822.
7. Brush JE Jr, Faxon DP, Salmon S, Jacobs AK, Ryan TJ. Abnormal endothelium-dependent coronary vasodilation in hypertensive patients. J Am Coll Cardiol. 1992;19:809–815.
8. Lehmam N, Erbel R, Malliodou AA, Kašců H, Möhlenkamp S, Moews S, Stang A, Roggenbuck U, Struckberg KH, Führer-Sakel D, Dragoano M, Budde T, Seibl R, Grönenmeyer D, Jockel KH; Heinz Nixdorf Recall Study Investigators. Accelerated progression of coronary artery calcification in hypertension but also prehypertension. J Hypertens. 2016;34:2233–2242. doi: 10.1097/HJH.0000000000001080.
9. Sipahi I, Tuzcu EM, Schomajen P, Wolfski KE, Nicholls SJ, Balog C, Crowe TD, Nissen SE. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol. 2006;48:833–836. doi: 10.1016/j.jacc.2006.05.045.
10. Candoni B, Ertas FS, Ozol D, Kaya CT, Kilickap M, Akyurek O, Atmaca Y, Kumbasar D, Erol C. Effect of hypertension on coronary remodeling patterns in angiographically normal or minimally atherosclerotic coronary arteries: an intravascular ultrasound study. Clin Exp Hypertens. 2012;34:2159–2219. doi: 10.3109/10641963.2012.665544.
11. Rigatto M, Al-Saawi J, Higano S, Miyake S, Holmes DR Jr, Lerman A. Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol. 2000;35:1654–1660.
12. Homsi R, Srinakart AM, Gieseck J, Yuceel S, Meier-Schroers M, Carinick P, Kopp M, Rose K, Doehner W, Tsai YS, Ouyang P, McDonald SD, Nieschlag E, Bax JJ, Hsich E, Tuzcu EM. Comparison of culprit lesion characteristics in STEMI patients with and without hypertension. Circ Cardiovasc Imaging. 2016;9:e00418. doi: 10.1161/CIRCIMAGING.115.00418.
13. Mancia G, Fogari R, Narkiewicz K, et al. 2013 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–2219. doi: 10.1093/eurheartj/eht151.
14. Steg PG, James SK, Atar D, et al; Task Force on the management of ST-segment elevation myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–2619. doi: 10.1093/eurheartj/ehs215.
What Is New?

- The pathological and prognostic significance of a history of hypertension was assessed in a reasonably large cohort of patients with acute ST-segment-elevation myocardial infarction.
- Hypertension was associated with a near 2-fold increased likelihood of all-cause death and heart failure.

What Is Relevant?

- A history of hypertension is associated with a worse prognosis.
- Patients with acute ST-segment-elevation myocardial infarction and a history of hypertension merit intensive medical management.

Summary

Our results confirm and extend previous investigations and support further research into therapeutic strategies that attenuate reperfusion injury within the infarct zone in patients with acute ST-segment-elevation myocardial infarction.